Subacute Cutaneous Lupus Erythematosus Management

Clinical Manifestations

The European League Against Rheumatism recommends assessing skin manifestations using the Cutaneous Lupus Disease Area and Severity Index (CLASI) 1
Inflammatory markers may be elevated in patients with subacute cutaneous lupus erythematosus 2

The American College of Rheumatology suggests hydroxychloroquine as the cornerstone of therapy for subacute cutaneous lupus erythematosus, with a recommended dose not exceeding 5 mg/kg real body weight 3
Regular ophthalmological screening is required for patients on hydroxychloroquine: at baseline, after 5 years, and yearly thereafter 3
Topical glucocorticoids are the mainstay of initial treatment for localized cutaneous manifestations, according to the European League Against Rheumatism 4
Topical calcineurin inhibitors may also be used for localized cutaneous manifestations 4
For widespread or severe disease, short-term systemic glucocorticoids may be needed, with a goal to minimize to less than 7.5 mg/day for chronic maintenance 4
NSAIDs may be helpful for pain and stiffness, particularly for musculoskeletal manifestations 5
Methotrexate is effective for various cutaneous manifestations, as recommended by the European League Against Rheumatism 4
Mycophenolate mofetil is effective for refractory cutaneous disease, according to the American College of Rheumatology 4
Azathioprine may be considered, particularly suitable for women contemplating pregnancy 3

Regular monitoring of disease activity using validated indices is crucial, as suggested by the European League Against Rheumatism 4
Photoprotection is essential for patients with subacute cutaneous lupus erythematosus 4
Assess and minimize risk factors for comorbidities, according to the American College of Rheumatology 3